## Measles Treatment: Supportive Care and Micronutrient Replacement **Key Point:** Measles is a viral infection with NO specific antiviral therapy. Management is entirely supportive, with emphasis on micronutrient repletion — particularly **Vitamin A supplementation**, which is the standard of care and reduces morbidity and mortality. ### Why Vitamin A? Vitamin A deficiency is common in measles and is associated with: - Increased severity of infection - Higher risk of secondary bacterial infections (otitis media, pneumonia) - Prolonged viral shedding - Increased mortality, especially in children <5 years and those with malnutrition **WHO and IAP Recommendation:** | Age Group | Dosing Regimen | |-----------|----------------| | < 6 months | 50,000 IU once daily for 2 days | | 6 months – 1 year | 100,000 IU once daily for 2 days | | > 1 year | 200,000 IU once daily for 2 days | | Repeat dose | 4 weeks later (if signs of deficiency persist) | **High-Yield:** Vitamin A supplementation reduces measles-related mortality by up to 23% in children and is mandatory in all cases, regardless of nutritional status. ### Supportive Measures 1. Fluid and electrolyte management 2. Nutritional support (high-calorie diet post-recovery) 3. Management of fever (paracetamol; avoid NSAIDs) 4. Antibiotic therapy ONLY if secondary bacterial infection develops (e.g., pneumonia, otitis media) 5. Isolation until 5 days after rash onset **Clinical Pearl:** Koplik spots (white spots on buccal mucosa appearing 2–3 days before rash) are pathognomonic for measles and appear during the prodromal phase. ### Why NOT Other Options? - **Ribavirin:** Used for severe respiratory syncytial virus (RSV) and some hemorrhagic fevers; no role in measles. - **Acyclovir:** Specific for herpes simplex virus and varicella-zoster virus; ineffective against measles virus. - **Oseltamivir:** Neuraminidase inhibitor for influenza; not indicated in measles.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.